Endothelin Role In COronary Microcirculation (ERICOM)
Determining the Role of Endothelin in Microcirculatory Function in Myocardial Ischaemia
Coronary microvascular dysfunction is an important cause of angina in patients who do not have significant blockages in the major coronary arteries. Previous studies suggest that endothelin-1, a naturally occurring substance that causes blood vessel constriction, may contribute to abnormalities in the coronary microcirculation.
The ERICOM study aims to investigate whether treatment with bosentan, an endothelin receptor antagonist, can improve coronary microvascular function in patients with angina and evidence of coronary microvascular dysfunction. Participants undergo cardiovascular magnetic resonance (CMR) imaging before and after treatment, and some participants also undergo invasive coronary physiological assessment.
The results of this study may improve understanding of the role of endothelin-1 in coronary microvascular dysfunction and help identify new treatment strategies for patients with angina and non-obstructive coronary artery disease.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Coronary microvascular dysfunction (CMD) is increasingly recognised as a major cause of myocardial ischaemia and angina in patients without obstructive epicardial coronary artery disease. CMD is a key mechanism underlying ischaemia with non-obstructive coronary arteries (INOCA) and is associated with impaired quality of life, recurrent healthcare utilisation, and adverse cardiovascular outcomes.
Endothelin-1 (ET-1) is a potent endogenous vasoconstrictor peptide that has been implicated in endothelial dysfunction, vascular inflammation, and microvascular dysregulation. Elevated circulating ET-1 concentrations have been reported in patients with microvascular angina and may contribute to increased coronary microvascular resistance and impaired myocardial perfusion.
The ERICOM study is a prospective, single-arm mechanistic study designed to investigate the relationship between ET-1 and coronary microvascular dysfunction and to assess the effects of endothelin receptor antagonism on coronary microvascular function.
Participants with angina symptoms and evidence of coronary microvascular dysfunction undergo baseline clinical assessment, blood sampling for ET-1 measurement, and stress cardiovascular magnetic resonance (CMR) imaging. Participants receive bosentan therapy for four weeks followed by repeat stress CMR imaging. A subset of participants undergoes invasive coronary angiography with physiological assessment, including measurements of coronary flow reserve (CFR), index of microcirculatory resistance (IMR), fractional flow reserve (FFR), and resting full-cycle ratio (RFR).
The primary objective is to determine whether bosentan therapy improves coronary microvascular function as assessed by serial CMR-derived myocardial perfusion measurements. Secondary objectives include evaluating associations between ET-1 concentrations and CMD, assessing relationships between invasive and non-invasive measures of coronary microvascular function, and exploring mechanistic pathways linking endothelin signalling and coronary microvascular disease.
The study is sponsored by Liverpool University Hospitals NHS Foundation Trust and conducted in accordance with Good Clinical Practice, Research Ethics Committee approval, and Health Research Authority approval.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
-
Liverpool, Regno Unito
- NHS University Hospitals of Liverpool Group
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Clinical diagnosis of symptomatic angina, defined as the presence of substernal chest pain or discomfort provoked by exertion or emotional stress and relieved by rest and/or glyceryl trinitrate (nitroglycerin).
- Age 18 years or older.
- Able and willing to provide written informed consent.
- Able and willing to adhere to study procedures and follow-up requirements.
Exclusion Criteria:
- Symptoms consistent with unstable angina, including:
- Angina at rest lasting more than 20 minutes.
- New-onset severe angina.
- Angina increasing in frequency, duration, or occurring at a lower threshold.
- Angina occurring following a recent myocardial infarction.
- Known significant coronary artery disease, defined as previous investigations demonstrating greater than 50% epicardial coronary artery stenosis.
- Uncontrolled hypertension, defined as clinic blood pressure greater than 140/90 mmHg despite treatment with three or more antihypertensive medications.
- Pregnancy or breastfeeding.
- Poorly controlled asthma as defined in the study protocol.
- Severe heart failure or symptoms of active heart failure.
- Significant chronic kidney disease, defined as estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73 m².
- Clinical evidence of active infection at the time of recruitment.
- Significant liver disease, defined as Child-Pugh Class B or C liver disease (or worse than Child-Pugh Class A).
- Systolic blood pressure less than 90 mmHg at the time of recruitment.
- Previously documented allergy or hypersensitivity to endothelin receptor antagonists.
- Concurrent use of medications contraindicated with endothelin receptor antagonist therapy.
- Requirement for invasive coronary angiography for another clinical indication, including but not limited to valvular heart disease assessment or intervention.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Diagnostico
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Interventional group
45 participants will undergo Cardiac MRI and invasive catheterization, and then given PO Endothelin Receptors Antagonists for 4 weeks.
Participants will then have a repeat cardiac MRI.
|
Cardiac stress/perfusion MRI scan
Invasive Coronary Angiogram with pressure wire assessments
Participants will be given PO Bosentan 125 mg BD for 4 weeks.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Myocardial Perfusion Reserve Index (MPRI) following Bosentan treatment
Lasso di tempo: Baseline and 4 weeks
|
Within-participant change in myocardial perfusion reserve index (MPRI) measured by stress cardiovascular magnetic resonance imaging before and after four weeks of Bosentan therapy.
|
Baseline and 4 weeks
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Michael Fisher, NHS University Hospitals of Liverpool Group
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- SP0323
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Cardiac MRI
-
St. Luke's-Roosevelt Hospital CenterCompletato
-
Seattle Institute for Cardiac ResearchCardiac Science Corporation.CompletatoFibrillazione atriale | Sincope | Tachicardia sopraventricolare | Pre-sincopeStati Uniti, Nuova Zelanda
-
University Health Network, TorontoCanadian Institutes of Health Research (CIHR)Non ancora reclutamentoMalattie cardiache | Malattia cardiovascolare | Conoscenza della salute, atteggiamenti, pratica | Comportamento, Salute
-
St Elizabeth HealthcareCompletatoSospetta aritmiaStati Uniti
-
Medtronic Cardiac Rhythm and Heart FailureCompletatoTachicardia, rientro nodale atrioventricolareStati Uniti
-
Medtronic Cardiac Rhythm and Heart FailureTerminato
-
Medtronic Cardiac Rhythm and Heart FailureCompletatoScompenso cardiaco Classe NYHA II | Insufficienza cardiaca Classe NYHA IIIStati Uniti
-
Respicardia, Inc.CompletatoApnea notturna | Disturbi respiratori del sonno | Respirazione periodica | Apnea centrale del sonno | La respirazione di Cheyne StokesStati Uniti, Polonia, Germania, Italia
-
University of MinnesotaTerminatoFibrillazione ventricolare | Infarto | Arresto cardiaco fuori dall'ospedale | Complicazione dell'ossigenazione extracorporea della membrana | Tachicardia ventricolare senza polsoStati Uniti
-
Imperial College LondonNational Institute for Health Research, United Kingdom; Imperial College Healthcare...RitiratoFibrosi miocardica | Arresto cardiaco | Insufficienza renale allo stadio terminale in dialisi | Malattia renale cronica Stadio V | Malattia renale cronica, stadio IV (grave)Regno Unito